about
Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysisEconomic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin.Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic VariantsMechanisms and assessment of statin-related muscular adverse effects.Dyslipidemia in special ethnic populationsSLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.Association of SLCO1B1 gene polymorphisms with toxicity response of high dose methotrexate chemotherapy in childhood acute lymphoblastic leukemia.Do physicians think genomic medicine will be useful for patient care?Myopathy in older people receiving statin therapy: a systematic review and meta-analysis.SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.Prescription medication changes following direct-to-consumer personal genomic testing: findings from the Impact of Personal Genomics (PGen) Study.Statin intolerance: diagnosis and remedies.Clinical association between pharmacogenomics and adverse drug reactions.Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challengeAdvances in the Pharmacogenomics of Adverse Drug Reactions.Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies.Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling.
P2860
Q28070052-49A2E205-3B08-4498-8ADD-62E498FEB6AEQ30490270-7E1367A2-98D7-4CDC-88BB-C94E0311D059Q34163351-E7BE3E31-CAC5-4D02-B480-B9B3E1FDF334Q34570995-A2EF2690-9F0D-45E2-9384-BE7206FDB432Q35573543-BB47DB0B-D857-4E43-B858-E8565B2E5D61Q35669829-EBC4F890-F3A2-4393-8246-5207CA64DEAAQ35791771-3AC726C3-D21F-4101-A338-43A2161F8218Q35827874-000B3DC3-D9DC-4090-8A51-A709C127467EQ36072457-7F6F33D9-FC98-4464-9F98-ECE9F951B050Q36184009-F6D8B93B-E678-414E-B992-50980BE9B2A4Q37716304-2943C6D8-E21E-48A3-B33E-C86B3B1D9C13Q38430744-42A6A0FC-85A4-4687-9F5F-33FD906C0F97Q38431150-DC88123C-41C7-4165-962A-06090C8B717EQ38644316-49A32567-C9FE-4F8E-9347-BA4573B8553EQ38663764-BB1BA2E1-4BA0-4445-8BD8-926B1E4B069CQ40759624-90C8787F-1FCA-450A-BF04-E0B9731A1220Q55393652-28F07D70-5864-47DF-B04D-8FB2E7446E96
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
SLCO1B1 Polymorphisms and Statin-Induced Myopathy.
@en
SLCO1B1 Polymorphisms and Statin-Induced Myopathy.
@nl
type
label
SLCO1B1 Polymorphisms and Statin-Induced Myopathy.
@en
SLCO1B1 Polymorphisms and Statin-Induced Myopathy.
@nl
prefLabel
SLCO1B1 Polymorphisms and Statin-Induced Myopathy.
@en
SLCO1B1 Polymorphisms and Statin-Induced Myopathy.
@nl
P2860
P1433
P1476
SLCO1B1 Polymorphisms and Statin-Induced Myopathy.
@en
P2093
Alison Stewart
P2860
P356
10.1371/CURRENTS.EOGT.D21E7F0C58463571BB0D9D3A19B82203
P577
2013-12-04T00:00:00Z